Jielun Zhu
Co-founder, Chief Financial and Business Officer
Bio:
Mr. Zhu is a leading KOL on biotech capital formation, business development and the “NewCo” model. He has recently co-founded the first “China-to-China NewCo” Excalipoint Therapeutics, successfully raising US$41 million from top-tier healthcare investors, setting a new record for seed round financing in China.
He previously served as CFO, CSO & CIO of well-known companies including I-Mab and Fapon Biotech, spearheading the planning and execution of capital market strategies, private and public market fundraisings, investor relation programs, business development activities, mergers & acquisitions, post-deal integration as well as start-up formation and incubation.
As a renowned industry executive and financier, Mr. Zhu boasts over 20 years of hands-on experience in capital formation for innovative biotech companies. He has led numerous landmark transactions, including the largest ever PIPE deal for Chinese biotechs and multi-billion dollar cross-border licensing transactions. At I-Mab, he led the company’s NASDAQ IPO and oversaw its spectacular post-IPO rise in market cap from US$800 million to US$7 billion within 18 months. At its peak, I-Mab was one of the highest profile Chinese biotech companies, in market cap, liquidity and research coverage. Mr. Zhu was also honored with top rankings from Institutional Investor (II) in the “Best CFO” categories in its All-Asia Executive Team survey.